“Real World Assessment of Once-a-Month Dosing of Lebrikizumab in Commercial Claims”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s747, https://doi.org/10.25251/6b1dka07.